10.62
-0.19 (-1.76%)
| Penutupan Terdahulu | 10.81 |
| Buka | 11.03 |
| Jumlah Dagangan | 14,816 |
| Purata Dagangan (3B) | 120,825 |
| Modal Pasaran | 399,254,656 |
| Harga / Pendapatan (P/E TTM) | 6.32 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.33 |
| Harga / Jualan (P/S) | 7.34 |
| Harga / Buku (P/B) | 1.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 - 11 May 2025 |
| Margin Keuntungan | 14.39% |
| Margin Operasi (TTM) | -105.99% |
| EPS Cair (TTM) | 0.580 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -65.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.66% |
| Nisbah Semasa (MRQ) | 21.88 |
| Aliran Tunai Operasi (OCF TTM) | -54.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -65.48 M |
| Pulangan Atas Aset (ROA TTM) | 0.51% |
| Pulangan Atas Ekuiti (ROE TTM) | 7.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Entrada Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.75 |
|
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.36% |
| % Dimiliki oleh Institusi | 80.37% |
| Julat 52 Minggu | ||
| Median | 20.00 (88.32%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 11 Feb 2026 | 20.00 (88.32%) | Beli | 10.60 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Entrada Therapeutics to Present at Upcoming Investor Conferences |
| 08 Jan 2026 | Pengumuman | Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases |
| 17 Dec 2025 | Pengumuman | Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 04 Dec 2025 | Pengumuman | Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |